Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.03.30.486409Source: DataRank Database

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2 is a research paper published in bioRxiv (Cold Spring Harbor Laboratory) (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

gisaid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (29)IDs (PubMed, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Chaitanya Kurhade ORCID,Hongjie Xia ORCID,Mingru Liu,Xuping Xie ORCID,Ping Ren ORCID

Live enrichment

PubMed:19162232 OpenAlex:https://openalex.org/W4220831088

National Institutes of Health

Grant: 3R01AI134907-03S2

A High-Throughput Platform for COVID-19 Serodiagnosis, Vaccine Evaluation, and Drug Discovery

National Institutes of Health

Grant: 5U01AI151801-04

West African Center for Emerging Infectious Diseases

National Institutes of Health

Grant: 5UL1TR001439-07

UTMB Clinical and Translational Science Award

National Institutes of Health

Grant: 1R43AI145617-01A1

Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats

greenLicense: cc-by-nc-nd

repositoryhttps://www.biorxiv.org/content/biorxiv/early/2022/03/31/2022.03.30.486409.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2022.03.30.486409

repositoryhttps://doi.org/10.1101/2022.03.30.486409

repositoryhttps://www.nature.com/articles/s41467-022-30580-5

Fields of Study

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

NeutralizationTiterSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)VirologyHeterologous2019-20 coronavirus outbreakChemistryBiologyMedicineVirusGeneInfectious disease (medical specialty)OutbreakCOVID-19 VaccinesNeutralization TestsSARS-CoV-2ScienceQCOVID-19HumansAntibodies, ViralArticle

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2

FAIR Checklist

Authors (7)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)